IV to PO Conversion of Acyclovir
The appropriate IV to PO conversion ratio for acyclovir is 5:1, meaning that oral acyclovir doses should be approximately 5 times higher than IV doses to achieve similar therapeutic effects due to the oral bioavailability of approximately 20%. 1
Dosing Considerations
Standard Dosing Equivalence
Disease-Specific Conversions
For Herpes Simplex Virus Encephalitis:
- IV therapy: 10 mg/kg every 8 hours for 14-21 days 2
- When switching to oral: 800 mg orally 5 times daily 4
For Severe HSV infections:
- Begin with IV acyclovir 5-10 mg/kg every 8 hours
- Switch to oral therapy once lesions begin to regress at 20 mg/kg (maximum 400 mg/dose) 3 times daily 3
Factors Affecting Conversion Decisions
Bioavailability Considerations
- Oral acyclovir has approximately 20% bioavailability 1
- This low bioavailability necessitates the 5:1 conversion ratio
- Absorption is not affected by food intake
Renal Function Adjustments
When converting from IV to oral in patients with renal impairment, adjust both formulations according to creatinine clearance:
| Creatinine Clearance (mL/min) | 800 mg Oral Dose Adjustment |
|---|---|
| >25 | 800 mg every 4 hours, 5x daily |
| 10-25 | 800 mg every 8 hours |
| <10 | 800 mg every 12 hours |
Clinical Pearls and Pitfalls
When to Convert from IV to PO
- Convert from IV to oral therapy when:
- Patient can tolerate oral medications
- Clinical improvement is observed
- Lesions begin to regress 3
- No signs of severe disease progression
Common Pitfalls
- Failing to adjust dosage in renal impairment can lead to crystalluria and elevated serum creatinine 5
- Inadequate hydration during IV therapy increases risk of renal complications
- Premature conversion to oral therapy in severe infections may result in treatment failure
- Failure to recognize that higher oral doses are needed due to lower bioavailability
Special Populations
For immunocompromised patients with HSV infections:
For HIV-infected patients:
- Higher oral doses are recommended (400 mg orally 3-5 times daily) 6
- Monitor closely for clinical response
Monitoring After Conversion
- Evaluate response within 72 hours after switching to oral therapy 3
- Monitor for adequate hydration to prevent crystalluria
- Watch for neurological symptoms which may indicate inadequate CNS penetration or neurotoxicity 3
- For herpes simplex encephalitis, consider CSF PCR at the end of therapy to confirm clearance 2
Remember that the 5:1 conversion ratio is based on the approximately 20% bioavailability of oral acyclovir, and this fundamental pharmacokinetic property guides appropriate dosing when transitioning from IV to oral therapy.